Endocrine最新文献

{"title":"The effect of antidiabetic drugs on bone metabolism: a concise review.","authors":"Stavroula Psachna, Maria Eleni Chondrogianni, Konstantinos Stathopoulos, Antonis Polymeris, Antonios Chatzigeorgiou, Efstathios Chronopoulos, Symeon Tournis, Eva Kassi","doi":"10.1007/s12020-024-04070-1","DOIUrl":"10.1007/s12020-024-04070-1","url":null,"abstract":"<p><p>Diabetes mellitus (DM) is a complex metabolic disorder characterized by chronic hyperglycemia, which derives from either insufficient insulin production [type 1 diabetes mellitus (T1DM)] or both impaired insulin sensitivity along with inadequate insulin production [type 2 diabetes mellitus (T2DM)] and affects millions of people worldwide. In addition to the adverse effects of DM on classical target organs and tissues, skeletal health can also be adversely affected. There is considerable evidence linking DM with osteoporosis. The fracture risk in patients with DM differs upon the type of diabetes, and it appears to be related to the type of anti-diabetic treatment. Antidiabetic drugs may have various effects on bone health. Most of them have neutral or even favorable effects on bone metabolism with the exception of thiazolidinediones (TZDs). Some studies suggest that TZDs may have negative impact on bone health by decreasing bone formation and increasing the fracture risk. There are also limited studies linking the use of canagliflozin, a Sodium-glucose contransporter-2 inhibitor (SGLT2i), with increased fracture risk. On the other hand, therapies that are based on incretin effect, like Dipeptidyl peptidase-4 inhibitors (DPP-4i) and Glucagon-like peptide-1 receptor agonizts (GLP-1RAs) might have positive effects on bone health by promoting bone formation. Herein we review the impact of antidiabetic drugs on bone health, highlighting the potential benefits and risks associated with these medications in an attempt to contribute to the development of personalized treatment strategies for individuals with DM.</p>","PeriodicalId":49211,"journal":{"name":"Endocrine","volume":" ","pages":"907-919"},"PeriodicalIF":3.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142478856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Renal pseudohypoaldosteronism type 1-an adult case series including a novel gene variant.","authors":"Jan Calissendorff, Henrik Falhammar","doi":"10.1007/s12020-024-04120-8","DOIUrl":"10.1007/s12020-024-04120-8","url":null,"abstract":"<p><strong>Purpose: </strong>Renal pseudohypoaldosteronism type 1 (PHA1) is a rare disease affecting infants. Symptoms are failure to thrive, vomiting, and weight loss. It is caused by gene variants in NR3C2 by which the mineralocorticoid receptor is dysfunctional, and patients develop hyponatremia, elevated plasma aldosterone, and renin but have normal blood pressure. Little is known about PHA1 in adults. We present four adults with PHA1, their clinical, biochemistry, and genetic data.</p><p><strong>Methods: </strong>Clinical and biochemical data were collected from the medical files and clinical examination of the participants. Genetic testing was performed.</p><p><strong>Results: </strong>Two adult dizygotic twins and their mother, as well as an adult man were included. One of the sisters and the man had had severe hyponatremia and been admitted several times as young infants, treated with sodium chloride and fludrocortisone. All had as adults elevated plasma aldosterone and normal sodium. The females now had normal plasma renin, but it was increased in the male. A novel genetic variant in NR3C2 was found in the twins and their mother (c.1816T>C, p.(Cys606Arg)). All had normal blood pressure and were asymptomatic.</p><p><strong>Conclusion: </strong>In adulthood, PHA1 seems to be asymptomatic and long-term consequences favorable.</p>","PeriodicalId":49211,"journal":{"name":"Endocrine","volume":" ","pages":"1285-1290"},"PeriodicalIF":3.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142755650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Roles of thyroid and leptin hormones and their crosstalk in male reproductive functions: an updated review.","authors":"Madhumanti Barman, Nelli Giribabu, Naguib Salleh","doi":"10.1007/s12020-024-04069-8","DOIUrl":"10.1007/s12020-024-04069-8","url":null,"abstract":"<p><strong>Purpose: </strong>This review aims to provide updated information regarding the role of thyroid and leptin hormones and their crosstalk in affecting the male reproductive function in hypothyroid and obesity conditions.</p><p><strong>Method: </strong>A wide literature search was made using online search engines on published articles using keywords including thyroid hormone, hypothyroidism, leptin hormone, hyperleptinemia, obesity, the relationship between thyroid and leptin hormones and male reproduction, and hypothyroidism, obesity, and male reproduction.</p><p><strong>Results: </strong>All information pertaining thyroid and leptin hormone effects on male reproduction, hypothyroidism, hyperleptinemia, and obesity effect on male fertility as well as the related molecular mechanisms are obtained.</p><p><strong>Conclusion: </strong>Thyroid and leptin hormones individually play a significant role in male reproduction. Alterations of these hormones' levels could adversely affect the male reproductive functions. PI3K/AKT signaling was found to be the major signaling pathway involved in mediating the effect of both hormones on male reproduction. Impaired crosstalk between the two hormones may occur in hypothyroidism with obesity which would contribute towards male reproductive dysfunction.</p>","PeriodicalId":49211,"journal":{"name":"Endocrine","volume":" ","pages":"891-906"},"PeriodicalIF":3.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142478844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Increased ferritin with contraceptives containing ethinyl estradiol drospirenone in polycystic ovary syndrome: a paradox of iron storage and iron deficiency.","authors":"Naile Gokkaya, Gizem Gecmez, Serhat Ozcelik, Mithat Biyikli, Kadriye Aydin","doi":"10.1007/s12020-024-04150-2","DOIUrl":"10.1007/s12020-024-04150-2","url":null,"abstract":"<p><strong>Objectives: </strong>The relationship between elevated ferritin levels and metabolic abnormalities in PCOS patients, and whether ferritin is a cause or a consequence, is still debated. This study aimed to evaluate the impacts of the fourth generation combined oral contraceptive containing ethinyl estradiol/drospirenone (EE 30 mcg/DRSP 3 mg), known for its favorable metabolic profile and lower side effect risk, on iron metabolism in PCOS patients, while also exploring the potential relationship between metabolic parameters and iron status.</p><p><strong>Methods: </strong>The retrospective analysis was conducted on 81 women aged 18-45, diagnosed with PCOS according to the Rotterdam criteria and treated with EE/DRSP for six months. Exclusion criteria were lack of data, secondary hyperandrogenemia, major medical conditions, or recent use of medications affecting hormone levels or iron metabolism. Pre- and post-treatment anthropometric measurements, hormonal and metabolic markers, and iron parameters were obtained from records.</p><p><strong>Results: </strong>Post-treatment ferritin levels significantly increased (p = 0.001), while hemoglobin, hematocrit, and transferrin saturation decreased especially in overweight/obese patients (p = 0.012, p = 0.002, p = 0.017 respectively), suggesting a response to inflammation rather than iron storage disorders. Although overall CRP levels did not change significantly, post-treatment CRP levels were higher in overweight/obese patients compared to lean PCOS patients (p = 0.003). Ferritin levels were positively correlated with body mass index (p = 0.008, r = 0.310), insulin resistance indices (p = 0.027, r = 0.248), and the free androgen index (p = 0.001, r = 0.367) after treatment. Pre-treatment menstrual cycle length had no effect on ferritin.</p><p><strong>Conclusions: </strong>The study revealed a paradoxical increase in ferritin levels with EE/DRSP treatment, highlighting the complex role of ferritin as a metabolic marker in PCOS patients, particularly in relation to obesity, which is typically associated with low-grade chronic inflammation.</p>","PeriodicalId":49211,"journal":{"name":"Endocrine","volume":" ","pages":"1314-1322"},"PeriodicalIF":3.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142911004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term safety and effectiveness of a somatropin biosimilar (Omnitrope^®) in children requiring growth hormone therapy: analysis of final data of Italian patients enrolled in the PATRO children study.","authors":"Lorenzo Iughetti, Franco Antoniazzi, Claudia Giavoli, Simonetta Bellone, Tommaso Aversa, Laura Guazzarotti, Maria Elisabeth Street, Emanuele Miraglia Del Giudice, Luca Persani, Gabriella Pozzobon, Letizia Ragusa, Stefano Stagi, Gianluca Tornese, Clara Zecchino, Chiara Mameli, Emiliano Zecchi, Paolo Fedeli, Markus Zabransky, Laura Lucaccioni, Stefano Zucchini","doi":"10.1007/s12020-024-04090-x","DOIUrl":"10.1007/s12020-024-04090-x","url":null,"abstract":"<p><strong>Purpose: </strong>Omnitrope^® (a somatropin biosimilar), used to treat growth disturbances, is considered to have a good safety profile in children. Here, we present the analysis of final data of the Italian cohort of the PAtients TReated with Omnitrope^® (PATRO) Children study.</p><p><strong>Methods: </strong>This multicenter, open-label, longitudinal, post-marketing surveillance study enrolled eligible children during 2010-2018. The primary objective was to assess the long-term safety of Omnitrope^® by recording all adverse events (AEs), serious AEs, and adverse drug reactions (ADRs). A secondary objective was to evaluate the long-term effectiveness of Omnitrope^® using height measurements.</p><p><strong>Results: </strong>A total of 375 patients were included in the Italian cohort of the PATRO Children study. After a mean ± standard deviation (SD) follow-up duration of 40.9 ± 24.6 months, 607 AEs were reported in 58.4% of patients, mostly of mild (52.5%) or moderate (15.7%) severity. The most common AEs were headache (11.7%), elevated insulin-like growth factor (IGF)-1 (4.8%), abdominal pain (4.3%), and pyrexia (3.7%). Sixty-seven ADRs occurred in 52 patients (13.9%); the most common ADRs were elevated IGF-1 (3.5%) and insulin resistance (2.9%). Mean ± SD height standard deviation scores in treatment-naïve patients increased from -2.5 ± 0.7 at baseline (n = 318) to -1.3 ± 0.7 at 5 years (n = 56) and to -0.8 ± 0.7 at 7.5 years (n = 13).</p><p><strong>Conclusions: </strong>This final analysis extends the interim analysis findings from the PATRO Children study and confirms the long-term safety and effectiveness of Omnitrope^® in Italian pediatric patients with growth disturbances.</p>","PeriodicalId":49211,"journal":{"name":"Endocrine","volume":" ","pages":"933-942"},"PeriodicalIF":3.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142752104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Microwave ablation for benign thyroid nodules with cosmetic problems and related factors for post-ablative complete relief: a two-center retrospective study.","authors":"Xiao-Long Li, Zi-Tong Chen, Yun-Jie Jin, Ben-Hua Xu, Ya-Dan Xu, Qiong Cao, Xiao-Wan Bo, Jie-Xian Wen, Zheng-Biao Ji, Pei-Li Fan, Hui-Xiong Xu","doi":"10.1007/s12020-024-04103-9","DOIUrl":"10.1007/s12020-024-04103-9","url":null,"abstract":"<p><strong>Purpose: </strong>To investigate the efficacy of ultrasound (US)-guided percutaneous MWA for benign thyroid nodules with cosmetic problems and identify related factors contributing to post-ablative complete relief (CR).</p><p><strong>Methods: </strong>This retrospective study reviewed the efficacy of MWA in treating thyroid nodules in patients with cosmetic problems who underwent MWA from January 2021 to May 2023. Patients were followed up at 1, 3, and 6 months after MWA. Pre-treatment clinical characteristics, conventional ultrasound (US) and contrast-enhanced ultrasound (CEUS) features were analyzed to explore their correlation with cosmetic improvement, defined as a cosmetic score of 1 or 2 at the 6-month follow-up. Univariable and multivariable regression analyses were carried out to identify variables associated with CR, and the related nomogram was established. Calibration curve and decision curve analysis were used to evaluate the nomogram performance.</p><p><strong>Results: </strong>118 patients with 118 nodules were included in the study. During the 1-, 3- and 6-month follow-up, the mean volume reduction ratios (VRR) were 2%, 36% and 73%, respectively. 22.0% (26/118), 57.6% (68/118), and 89.8% (106/118) patients achieved CR of cosmetic problems at 1, 3, and 6 months after MWA. In multivariable analysis, three variables (i.e., non-hashimoto's thyroiditis [HT] [OR: 90.036, P = 0.001], nodule location not close to danger triangle area [OR: 66.812, P = 0.003], early hyperenhancement on CEUS [OR: 0.035, P = 0.024]) were found to be closely associated with CR of cosmetic problems at 6 months after MWA. A nomogram model was constructed, and its accuracy was well validated (i.e., C-index = 0.914).</p><p><strong>Conclusion: </strong>MWA was effective and safe for treating benign thyroid nodules with cosmetic problems. Non-HT, nodule location not close to danger triangle area, and early hyperenhancement on CEUS were associated with CR of cosmetic problems after MWA.</p>","PeriodicalId":49211,"journal":{"name":"Endocrine","volume":" ","pages":"1080-1089"},"PeriodicalIF":3.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142752105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Racial and ethnic disparities in the risk of second primary malignancies in differentiated thyroid cancer patients: a population-based study.","authors":"Xingling Guo, Liang He, Haifeng Xu, Renjie Chen, Zhenyu Wu, Yulong Wang, Ying Wu","doi":"10.1007/s12020-024-04104-8","DOIUrl":"10.1007/s12020-024-04104-8","url":null,"abstract":"<p><strong>Background: </strong>There is limited evidence on the risks of second primary malignancies (SPMs) among patients with differentiated thyroid cancer (DTC), particularly in relation to racial disparities. We aim to examine racial and ethnic disparities in the risk and temporal patterns of SPMs among DTC survivors in the U.S.</p><p><strong>Methods: </strong>This retrospective cohort study, grounded in population-based data from the Surveillance, Epidemiology, and End Results (SEER) program, focused on DTC patients diagnosed between 2004 and 2015. Standardized incidence ratios (SIR) and 95% confidence intervals were employed to estimate high-risk sites for SPMs among different races. The competing risks model was applied to assess SPM risks and risk factors across racial groups, with mediation analysis conducted for selected variables.</p><p><strong>Results: </strong>Among 90,186 DTC patients, 8.3% developed SPMs. DTC survivors face a 15% higher risk of developing SPMs compared to the general population. Blacks demonstrated a significantly lower risk of SPMs, while other ethnic groups faced higher risks than Whites. Specific SPM risk factors for Whites, Blacks, and other ethnicities were receiving radiotherapy, diagnosis at a distant stage, and tumors exceeding 40 mm, respectively. Specifically, Blacks and other ethnic groups primarily encounter SPMs in the salivary glands, soft tissues, hematologic, and urinary systems, often earlier than in Whites. Conversely, Whites had a broader distribution of risk sites, with a notable risk for other endocrine tumors, manifesting 48-87 months post-diagnosis.</p><p><strong>Conclusions: </strong>DTC patients show significant racial and ethnic disparities in high-risk sites, temporal patterns, SPM risks and risk factors. Personalized follow-up for diverse ethnic backgrounds can ameliorate disparities, enhancing SPM risk and survival outcomes.</p>","PeriodicalId":49211,"journal":{"name":"Endocrine","volume":" ","pages":"1090-1099"},"PeriodicalIF":3.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142752131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Aberrant promoter methylation, expression and function of RASSF1A gene in a series of Italian parathyroid tumors.","authors":"Chiara Verdelli, Federico Pio Fabrizio, Paola Maroni, Annamaria Morotti, Giulia Stefania Tavanti, Silvia Carrara, Vito Guarnieri, Filomena Cetani, Alfredo Scillitani, Riccardo Maggiore, Francesca Perticone, Valentina Vaira, Lucia Anna Muscarella, Sabrina Corbetta","doi":"10.1007/s12020-024-04113-7","DOIUrl":"10.1007/s12020-024-04113-7","url":null,"abstract":"<p><strong>Purpose: </strong>Aberrant epigenetic features are key events involved in parathyroid tumorigenesis, including DNA methylation, histone methylation, and non-coding RNAs. Ras Association Domain Family Protein1 Isoform A (RASSF1A) and Adenomatous Polyposis of Colon (APC) are frequently downregulated in human cancers. Here, we investigated their deregulated expression and the potential role in parathyroid neoplasms.</p><p><strong>Methods: </strong>methylation of RASSF1A and APC promoters was analyzed in a series of parathyroid adenomas (PAds, n = 80) and parathyroid carcinomas (PCas, n = 9) from Italian patients with primary hyperparathyroidism, RESULTS: RASSF1A and APC promoter methylation occurred in about 90% of PAds samples. PCas displayed RASSF1A promoter methylation, while APC promoter was methylated only in 2 samples. Of note, RASSF1A promoter methylation negatively correlated with PAds tumor size. However, RASSF1A transcript and protein levels were reduced in PAds and PCas compared with parathyroid normal glands. Investigating the potential mechanism involved in RASSF1A promoter methylation, we found that DNA methyltransferases (DNMTs) activity was variable in PAds and inversely correlated with RASSF1A protein levels. In addition, the RASSF1A promoter methylation negatively correlated with long-non-coding Antisense Intronic Noncoding RASSF1A (ANRASSF1A) mRNA levels, excluding the involvement of ANRASSF1 in RASSF1A regulation. In HEK293A cells transfected with the calcium sensing receptor (CASR), loss of RASSF1A increased basal phosphorylated Extracellular signal-regulated kinase (pERK/ERK) levels blunting the CASR-induced increases.</p><p><strong>Conclusion: </strong>RASSF1A and APC promoter methylation is a hallmark of parathyroid tumors; deregulation of DNMTs activity contributes to modulation of RASSF1A expression. Loss of RASSF1A may be involved in the tuning of ERK pathway in parathyroid tumors.</p>","PeriodicalId":49211,"journal":{"name":"Endocrine","volume":" ","pages":"1246-1256"},"PeriodicalIF":3.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142741108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of nodal status evaluation on therapeutic strategy for clinically unifocal T1b/small T2 node negative papillary thyroid carcinoma.","authors":"Antonio Laurino, Francesco Pennestrì, Priscilla Francesca Procopio, Annamaria Martullo, Gloria Santoro, Pierpaolo Gallucci, Francesca Prioli, Luca Sessa, Esther Diana Rossi, Alfredo Pontecorvi, Carmela De Crea, Marco Raffaelli","doi":"10.1007/s12020-024-04101-x","DOIUrl":"10.1007/s12020-024-04101-x","url":null,"abstract":"<p><strong>Purpose: </strong>In absence of nodal metastases or aggressive features, thyroid lobectomy (TL) should be preferred over total thyroidectomy (TT) for 1-4 cm unifocal, papillary thyroid carcinoma (PTC). However, occult, despite non-microscopic (≥2 mm), nodal metastases may be present in clinically node-negative (cN0) PTC.</p><p><strong>Methods: </strong>Among 4216 thyroidectomies for malignancy (2014-2023), 110 TL plus ipsilateral central neck dissection (I-CND) were scheduled for unifocal cT1b/small cT2 (≤3 cm) cN0 PTCs. Frozen section examination (FSE) of removed nodes was performed: when positive, completion thyroidectomy (CT) was accomplished during the same procedure. In presence of aggressive pathologic features, CT was suggested within 6 months from index operation.</p><p><strong>Results: </strong>FSE was positive for occult not-microscopic nodal metastases in 33 cases (30%), underwent synchronous CT. Among the remaining 77 patients, 24 (31.2%) were scheduled for CT, after multidisciplinary tumor board discussion, due to at least 2 high-risk factors. The median number of removed and metastatic nodes was 8 (5-11) and 2 (1-5), respectively, at definitive histopathology. Furthermore, multifocality was present in 53 (48.2%) cases, lymphovascular invasion in 66 (60%) cases, aggressive subtypes in 20 (18.2%) cases and extracapsular invasion in 5 (4.5%) cases. Overall, 57 (51.8%) patients underwent immediate or delayed CT.</p><p><strong>Conclusion: </strong>More than 50% of patients with unifocal cT1b/small cT2 cN0 PTC scheduled for TL may be eligible for CT because of aggressive tumor features. An intraoperative decision-making approach based on I-CND and nodes FSE may ensure accurate staging and risk stratification, thus reducing the risk of recurrence and the need for reoperation.</p>","PeriodicalId":49211,"journal":{"name":"Endocrine","volume":" ","pages":"1070-1079"},"PeriodicalIF":3.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142669549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deep learning based analysis of dynamic video ultrasonography for predicting cervical lymph node metastasis in papillary thyroid carcinoma.","authors":"Tingting Qian, Yahan Zhou, Jincao Yao, Chen Ni, Sohaib Asif, Chen Chen, Lujiao Lv, Di Ou, Dong Xu","doi":"10.1007/s12020-024-04091-w","DOIUrl":"10.1007/s12020-024-04091-w","url":null,"abstract":"<p><strong>Background: </strong>Cervical lymph node metastasis (CLNM) is the most common form of thyroid cancer metastasis. Accurate preoperative CLNM diagnosis is of more importance in patients with papillary thyroid cancer (PTC). However, there is currently no unified methods to objectively predict CLNM risk from ultrasonography in PTC patients.This study aimed to develop a deep learning (DL) model to help clinicians more accurately determine the existence of CLNM risk in patients with PTC and then assist them with treatment decisions.</p><p><strong>Methods: </strong>Ultrasound dynamic videos of 388 patients with 717 thyroid nodules were retrospectively collected from Zhejiang Cancer Hospital between January 2020 and June 2022. Five deep learning (DL) models were investigated to examine its efficacy for predicting CLNM risks and their performances were also compared with those predicted using two-dimensional ultrasound static images.</p><p><strong>Results: </strong>In the testing dataset (n = 78), the DenseNet121 model trained on ultrasound dynamic videos outperformed the other four DL models as well as the DL model trained using the two-dimensional (2D) static images across all metrics. Specifically, using DenseNet121, the comparison between the 3D model and 2D model for all metrics are shown as below: AUROC: 0.903 versus 0.828, sensitivity: 0.877 versus 0.871, specificity: 0.865 versus 0.659.</p><p><strong>Conclusions: </strong>This study demonstrated that the DenseNet121 model has the greatest potential in distinguishing CLNM from non-CLNM in patients with PTC. Dynamic videos also offered more information about the disease states which have proven to be more efficient and robust in identifying CLNM compared to statis images.</p>","PeriodicalId":49211,"journal":{"name":"Endocrine","volume":" ","pages":"1060-1069"},"PeriodicalIF":3.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142649438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}